Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 203 participants.

Also called NCT04707508

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 203 participants (enrolled count) (from the registry)
Sponsor
Nantou Christian Hospital (from the registry)
Registry
  • NCT NCT04707508
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04707508. Non-randomized; no masking; primary purpose treatment. Start 2017-12-01 (actual); primary completion 2019-01-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Valsartan 80 mg and metformin
Intervention (Drug)
Metformin
Lead sponsor
Nantou Christian Hospital (class: other)

Record details

Record id
cardio:ct-nct04707508
Content hash
07683645508708555d4e2205b65c11fa15fb727ee3a5a31b2d334eb9a602284c